Article | July 22, 2021

What Sets Oncology Clinical Studies Apart From Other Trials? Four Top Differentiators

Source: Biorasi
oncology PS

Complex. Life-Saving. Competitive. These are just a few of the words that come to mind when describing oncology clinical trials.

In some ways, oncology studies start out similarly to other therapeutic indications, such as dermatology or neurology, requiring a robust protocol, patient engagement, and data capture in order to keep the trial on-time and on-budget. However, oncology trials differ radically in relation to the facilitation of Phase I/II of the study, biomarkers, drug characteristics, and competition for patients.

Biorasi recently spoke at length with Alex A. Adjei, MD, PhD, FACP, Professor of Oncology and Pharmacology at Mayo Clinic and Mayo College of Medicine, and new member of our growing Scientific Advisory Board, about differentiators in oncology studies that make them unique among other trials and therapeutic indications.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader